dr. ramalingam on next steps with nivolumab/ipilimumab in nsclc
Published 4 years ago • 2.5K plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
2:15
dr. ramalingam on pembrolizumab and chemotherapy in nsclc
-
1:19
dr. ramalingam on emerging combination regimens in nsclc
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:01
dr. heymach on nivolumab for lung cancer
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
1:38
dr. ramalingam on avelumab plus lorlatinib in nsclc
-
1:03
dr. herbst on combination of nivolumab and ipilimumab in patients with nsclc
-
0:50
checkmate 227 induced manageable toxicities with immunotherapy combination in nsclc
-
0:51
dr. chiang on toxicities with ipilimumab plus nivolumab in small cell lung cancer
-
3:13
dr. ramalingam on side effects associated with immunotherapy in lung cancer
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
1:34
dr. sharpless on managing toxicities with nivolumab/ipilimumab in melanoma
-
1:02
dr. hellmann on nivolumab in combination with ipilimumab for small cell lung cancer
-
1:21
dr. suresh s. ramalingam on optimizing immunotherapies in lung cancer
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
0:39
dr. atkinson on when to use nivolumab monotherapy versus nivolumab/ipilimumab combination
-
1:06
dr. patrick m. forde on next steps after failed checkmate-026 study in nsclc